Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-551-9 | CAS number: 976-56-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
In two subchronic oral feeding studies with a structural analogue, no effects on reproductive organs have been observed.
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No animal studies were conducted with the test substance to investigate possible substance-related effects on the reproductive performance. For a structural analogue, two subchronic feeding studies are available. Please refer to the Annex of the CSR for the read across justification.
When given to male and female CD rats at 700, 2000, 6000 ppm no findings
of pathological significance were noted in testes and epididymis of
males as well as in uterus and ovaries of females in comparison with
untreated control animals (1979). Similarly, in a subchronic oral
feeding study conducted in Beagle dogs after exposure to 200, 600, 2000
ppm no findings of pathological significance were noted in testes and
epididymis of males as well as in uterus and ovaries of females in
comparison with untreated control animals (1980).
Effects on developmental toxicity
Description of key information
In a prenatal developmental toxicity study with a structurally related compound (1983, OECD 414) 25 pregnant Tif:RAIf (SPF) rats per dose were treated daily by gavage with 400, 1200 and 2400 mg test substance per kg bodyweight from day 6 to 15 of gestation. No adverse effects have been observed. Based on the findings a NOEL of 2400 mg/kg bw (highest dose tested) was deduced for developmental toxicity.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Nov 1982 - Mar 1983
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Guideline study performed under GLP-like quality control. No data on purity were available. Dosing was performed from day 6 to 15 of gestation only.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 12 May 1981
- Deviations:
- no
- GLP compliance:
- no
- Remarks:
- predating GLP, QAU statement included
- Limit test:
- no
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature
- Stability under test conditions: Determined by the sponsor
- Solubility and stability of the test substance in the solvent/vehicle: Insoluble in water
FORM AS APPLIED IN THE TEST (if different from that of starting material): Suspension - Species:
- rat
- Strain:
- other: Sprague-Dawley derived Tif:RAIf (SPF) rats
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: closed breeding colony, Ciba-Geigy WST
- Age at study initiation: 2 months
- Weight at study initiation: 180-200 g
- Housing: 5 per cage in Makrolon cages
- Diet: NAFAG No. 890, ad libitum
- Water: ad libitum
- Acclimation period: day 0 to day 6 post coitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21+/-2
- Humidity (%): 55+/-10
- Photoperiod: 12 hrs dark / 12 hrs light - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5%
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The suspension of the test material was freshly prepared daily by homogenization and stirring (magnetic stirrer), and administered at a rate of 10 ml/kg of body weight.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Insoluble in water
- Amount of vehicle (if gavage): 10 mL/kg bw - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- The females were mated overnight with males of proven fertility in the ratio of 1 male / 3 females. The day on which spermatozoa were found in the vaginal smear or a vaginal plug was observed, was designated as day 0 of pregnancy.
- Duration of treatment / exposure:
- Day 6 to day 15 of pregnancy
- Frequency of treatment:
- Once daily
- Duration of test:
- until day 21 of gestation
- Dose / conc.:
- 400 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 400 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 25 pregnant rats
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Doses were based on results of a preliminary study, where 10 rats were dosed with vehicle or 2000 mg/kg bw test substance. The dams of the experimental group (2000 mg/kg bw) reacted to the treatment by some reduction in body-weight gain and food intake in comparison with the vehicle control. Concerning the progeny, no abnormalities were revealed by the external examination; the average weight of the foetuses of the 2000 mg/kg bw dose group was not significantly diminished in comparison with the vehicle control (Student's t test, one-tailed, observed p < 0.01). - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily during treatment period
BODY WEIGHT: Yes
- Time schedule for examinations: Daily during treatment period
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- organs
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No data
- Number of corpora lutea: No data
- Number of implantations: No data
- Number of resorptions: Yes
- Number of abortions
- Mucosa and contents, including amniotic fluid and placentae - Fetal examinations:
- - External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes [One third per litter]
- Skeletal examinations: Yes: [ Two third per litter ]
- Head examinations: No data
- Sex determination
- Weighing
- Uterine horns showing no evident implantation sites were placed into a solution of ammonium sulfide to visualize possible haemorrhagic alterations in such sites. - Statistics:
- The numbers of embryonic and/or foetal deaths (resorptions) (Chi*-test, Yates' correction, observed p > 0.01).
The male to female ratios of the foetuses (Chi* -test, Yates' correction, observed p > 0.05). - Historical control data:
- Spontaneous data characteristic of the breed of rats used in the present study refer to a series of untreated controls ("historical" or cumulative control) observed over a period of 69 months (listed in the study report).
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- 1 female (400 mg/kg bw) died on day 6 in consequence of an intubation error. No spontaneous deaths occured.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- food consumption was reduced in all exposure groups (from day 6 of pregnancy)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Signs of inflammation of the liver in one female vehicle control
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- not examined
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- One female vehicle control and one female exposed to 2400 mg/kg delivered "spontaneously" (i.e. shortly before sacrifice on day 21 p.c.) and were not taken into further consideration of data.
- Changes in number of pregnant:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 2 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: abscence of adverse effects for the tested doses
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In comparison with the vehicle control, the average body-weight of the live fetuses was not diminished at either dose. A slight but significant
increase was noted for the live fetuses of the intermediate and, at a lower extent, of the high-dose group (Student's t test, onetailed,
observed p < 0.01). This finding, however, is not assumed to be of a biological relevance. - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- not examined
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One fetus with omphalocele in the high-dose group, mandibular aplasia in one fetus of the intermediate-dose group
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The skeletal assessment revealed instances of irregular sternebral ossification in the dose groups and in the vehicle control
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One fetus with anasarca in the vehicle control, two fetuses from one
litter with subpleural haemorrhage in the low-dose group, one fetus displaying partial aplasia of the lungs in the intermediate-dose group - Dose descriptor:
- NOAEL
- Effect level:
- 2 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: abscence of adverse effects for the tested doses
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- Based on the results and under the condition chosen, the test article is considered to be not teratogenic.
- Executive summary:
In a prenatal developmental toxicity study following OECD guideline 414, 25 pregnant Tif:RAIf (SPF) rats per dose group were treated daily with the test article by gavage at 400, 1200, 2400 mg/kg body weight from day 6 to 15 of gestation. Dams were killed on day 21 and fetuses removed by Caesarian section. Body-weight gain was comparable for the dams of all groups. Food consumption of the experimental groups, however, showed some reduction during the treatment period (from day 6 of pregnancy) in comparison with the vehicle control. One female of the low dose group died due to an intubation error. Females No. 4 (vehicle control) and No. 78 (2400 mg/kg) delivered "spontaneously" (i.e. shortly before sacrifice on day 21 p.c.) and were not taken into further consideration of data.
The rates of implantation sites per female were comparable for all groups. The numbers of embryonic and/or fetal deaths (resorptions) were not increased at either dose. The male to female ratios of the fetuses were also comparable for all groups. In comparison with the vehicle control, the average body-weight of the live fetuses was not diminished at either dose. A slight but significant increase was noted for the live fetuses of the intermediate and, at a lower extent, of the high-dose group. This finding, however, is not assumed to be of a biological relevance. The gross and/or visceral examination of the live fetuses revealed one fetus with anasarca in the vehicle control, two fetuses from one litter with subpleural haemorrhage in the low-dose group, one fetus each displaying mandibular aplasia and partial aplasia of the lungs, respectively, in the intermediate dose and one fetus showing omphalocele in the high-dose group. The skeletal assessment revealed instances of irregular sternebral ossification in the dose groups and in the vehicle control. Concerning the status of skeletal maturation of the fetuses shortly before term, no delay of ossification could be found for the experimental groups in comparison with the vehicle control. Based on the findings a NOAEL of 2400 mg/kg body weight (highest dose tested) was derived for maternal and developmental toxicity.
Reference
Table 1: Summarized reproduction data of the main study.
Dose group (mg/kg d) |
0 |
400 |
1200 |
2400 |
Historical control |
Spontaneous deaths |
0/25 |
0/24 |
0/25 |
0/25 |
0/842 |
Body-weight gain (%) |
+10.3 |
+10.3 |
+13.0 |
+9.3 |
|
Females with deciduomata |
0/25 |
0/24 |
0/25 |
0/25 |
1/842 |
Females with implantations |
22/25 |
22/24 |
24/25 |
22/25 |
784/842 |
Implantations/female (mean, SD) |
15.4±2.0 |
15.7±2.9 |
14.5±1.9 |
15.0±2.7 |
13.09±2.33 |
Females with total abortion |
0 |
0 |
0 |
0 |
0/784 |
Females with partial abortion |
0 |
0 |
0 |
0 |
2/784 |
Embryonal deaths (resorptions) |
3.8 |
7.0 |
8.4 |
8.2 |
8.74 |
Foetal deaths (resorptions) |
0.3 |
0.3 |
0 |
0.3 |
0.28 |
Dead foetuses |
0 |
0 |
0 |
0 |
0.13 |
Number of live foetuses (males-females) |
155-170 |
166-154 |
160-158 |
146-155 |
4554-4765 |
Percent males of live foetuses |
47.7 |
51.9 |
50.3 |
48.5 |
48.9 |
Average weight of live foetuses (g) |
5.3±0.5 |
5.3±0.4 |
5.4±0.4 |
5.4±0.4 |
5.34±0.45 |
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 2 400 mg/kg bw/day
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No data for the test article are available. Therefore, data obtained with a structurally related compound is used to assess developmental toxicity. Please refer to the Annex of the CSR for the read across justification.
In a prenatal developmental toxicity study following OECD guideline 414, 25 pregnant Sprague-Dawley derived Tif:RAIf (SPF) rats per dose group were treated daily with the test article by gavage at 400, 1200, 2400 mg/kg body weight from day 6 to 15 of gestation. Dams were killed on day 21 and fetuses removed by Caesarian section. Body-weight gain was comparable for the dams of all groups. Food consumption of the experimental groups, however, showed some reduction during the treatment period (from day 6 of pregnancy) in comparison with the vehicle control. One female of the low dose group died due to an intubation error. The rates of implantation sites per female were comparable for all groups. No differences between control and test groups were reported regarding fetal death (resorption), male to female ratio of fetuses and average fetal body weight. A slight but significant increase was noted for the live fetuses of the intermediate and, at a lower extent, of the high-dose group. This finding, however, is not assumed to be of a biological relevance. Some instances of anomalies and/or malformations were recorded for the dose groups as well as for the vehicle control: two fetuses from one litter of the low dose displayed subpleural hemorrhage; mandibular aplasia and partial aplasia of the lungs, respectively, were found in one fetus each of the intermediate dose, omphalocele occurred in one fetus of the high dose and anasarca in one fetus of the vehicle control group. These findings are considered to be of a spontaneous origin and not related to the treatment. The incidences of mandibular aplasia, omphalocele and anasarca were found to be 0.05%, 0.04% and 0.12%, respectively, in the historical control population of the breed of rats used for the present experiment. Likewise, the occurrence of sternebral anomalies in all groups was not assumed to be of an experimental significance, the overall incidence of sternebral anomalies being 0.37% in the historical control. Concerning the status of skeletal maturation of the fetuses, no delay of ossification could be found for the experimental groups in comparison with the vehicle control. Based on the findings a NOAEL of 2400 mg/kg body weight (highest dose tested) was derived for maternal and developmental toxicity.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008 (CLP). As a result the substance is not classified for reproduction toxicity under Regulation (EC) No 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.